dm+d
425256004
Articles
Preparing to use ranibizumab biosimilar
Good governance when implementing ranibizumab biosimilar
The licence and supporting evidence for ranibizumab biosimilar
Safety in Lactation: Subfoveal choroidal neovascularisation
Refrigerated Storage
Lucentis
Novartis PharmaceuticalsIn the event of an inadvertent temperature excursion the following data may be used:
Prior to use, the unopened product may be kept at room temperature (25°C) for up to 24 hours.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Ongavia
Bioeq/Midas. UK Sales and Marketing: TevaIn the event of an inadvertent temperature excursion the following data may be used:
The following temperature excursions are considered non-critical:
- Between 8°C and 25°C for a maximum duration of 16 hours
- Between 25°C and 30°C for a maximum duration of 4 hours
- Between -10°C and 2°C for a maximum duration of 24 hours
Prior to use, the unopened product may be kept at room temperature (25°C) for up to 24 hours.
Contact Teva in cases where additional stability data is required. Refer to the electronic medicines compendium (eMC) at https://www.medicines.org.uk for company contact details and manufacturer’s product literature.